Abstracts tagged "Osteoarthritis"

Abstract Number: 1643 • ACR Convergence 2020
Evaluating Analgesic Response to Subcutaneous Tanezumab in Patients with Inadequate Treatment Response to Other Analgesics Based on Daily E-pain Diaries: A Pooled Analysis of 2 Randomized, Placebo-controlled Studies
Thomas Schnitzer¹, Francis Berenbaum², Isabelle Davignon³, Ruoyong Yang⁴, Lars Viktrup⁵, Christine West³ and Kenneth Verburg⁶, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc.,, New York, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Pfizer Inc, Groton
Background/Purpose: Tanezumab is a monoclonal antibody against nerve growth factor being investigated for treatment of the signs and symptoms of osteoarthritis (OA). Subcutaneous tanezumab was…
Abstract Number: 1659 • ACR Convergence 2020
Synergistic Effect of Quadriceps Weakness and Obesity in Women at Risk of Knee Osteoarthritis
Jose Rubio¹, David Felson², Xiaoyang Chen³, Kathy Bacon⁴, Neil Segal⁵, Michael Nevitt⁶, Cora Lewis⁷, Tuhina Neogi² and Devyani Misra⁸, ¹Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Boston University, Boston, MA, ⁴Boston University School of Medicine, Boston, ⁵University of Kansas Medical Center, Kansas City, ⁶University of California San Fransisco, Orinda, CA, ⁷University of Alabama Birmingham, Birmingham, AL, ⁸Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Quadriceps weakness is associated with an increased risk of incident symptomatic and radiographic knee osteoarthritis (OA), particularly in women. Stronger quadriceps muscles may confer…
Abstract Number: 0192 • ACR Convergence 2020
Influence of Inflammatory and Non-inflammatory Rheumatic Disorders on the Clinical and Biological Profile of Adult-onset Diabetes
Jerome Avouac¹, Muriel Elhai², Marine Forien³, Jeremie Sellam⁴, Florent Eymard⁵, Anna Molto⁶, Frederic Banal⁷, Joel Damiano⁸, Philippe Dieude³, Etienne Larger⁹ and Yannick Allanore¹, ¹Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland., Schlieren, Switzerland, ³Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France, ⁴AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ⁵APHP Henri Mondor Hospital, Creteil, France, ⁶Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, ⁷Service de Rhumatologie Hôpital d'instruction des armées Bégin, Saint Mande, France, ⁸Service de Rhumatologie Hôpital Sainte Camille, Bry-Sur-Marne, Ile-de-France, France, ⁹Université de Paris, Service de Diabétologie, Hôpital Cochin, AP-HP.CUP, Paris, Ile-de-France, France
Background/Purpose: To compare the profile of adult-onset diabetes in patients with rheumatoid arthritis (RA) or osteoarthritis (OA), two chronic diseases leading to disability differing by…
Abstract Number: 0702 • ACR Convergence 2020
Distinct Murine Cartilage Microbial DNA Signatures Are Seen in High Fat Diet-Induced Obesity and Aging
Christopher Dunn¹, Cassandra Garman², Jake Martin², Vladislav Izda², Cassandra Velasco² and Matlock Jeffries², ¹University of Oklahoma Health Sciences Center, Oklahoma Cityq, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: The strongest nongenetic risk factors for primary knee OA are advanced age and obesity. We have previously shown a human cartilage microbial DNA signature…
Abstract Number: 1102 • ACR Convergence 2020
Neuropathic Pain in Inflammatory Hand Osteoarthritis(OA) Lowers Quality of Life and May Require Another Approach Than Anti-inflammatory Treatment
Coen van der Meulen¹, Lotte van de Stadt¹, Féline Kroon², Marion Kortekaas¹, Annelies Boonen³, Stefan Böhringer⁴, Monique Reijnierse², Frits Rosendaal², Naghmeh Riyazi⁵, Mirian Starmans⁶, Franktien Turkstra⁷, Jende Van Zeben⁸, CF Allaart² and Margreet Kloppenburg², ¹LUMC, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Maastricht University Medical Center, Maastricht, Netherlands, ⁴LUMC, Leiden, ⁵HAGA ziekenhuis, the hague, Netherlands, ⁶Zuyderland MC, Heerlen, Netherlands, ⁷Reade, Amsterdam, Netherlands, ⁸Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands
Background/Purpose: To investigate whether neuropathic pain is present in patients with inflammatory hand OA, to investigate characteristics of those patients and the impact of neuropathic…
Abstract Number: 1118 • ACR Convergence 2020
Bone Marrow Lesion Scores in Patients with Knee Osteoarthritis Undergoing Tibial Osteotomy: Reliability and Concurrent Validity of the Knee Inflammation MRI Scoring System (KIMRISS)
Jenna Schulz¹, Trevor Birmingham¹, Walter Maksymowych², Robert G Lambert³, Stephany Pritchett⁴, Frank Beier¹, J. Robert Giffin⁵ and Tom Appleton⁶, ¹Western University, London, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of Alberta and CARE Arthritis, Edmonton, AB, Canada, ⁴London Health Sciences Centre, London, Canada, ⁵Western University and London Health Sciences Centre, London, Canada, ⁶The University of Western Ontario, LONDON, ON, Canada
Background/Purpose: Bone marrow lesions (BMLs) commonly occur in knee osteoarthritis (OA) and are associated with increased risk of cartilage damage and pain. The Knee Inflammation…
Abstract Number: 1484 • ACR Convergence 2020
Efficacy of Tocilizumab in Patients with Hand Osteoarthritis: Double Blind, Randomized, Placebo Controlled, Multicenter Trial
Pascal Richette¹, Augustin Latourte², Jeremie Sellam³, Daniel Wendling⁴, Muriel Piperno⁵, Philippe Goupille⁶, Yves-Marie Pers⁷, Florent Eymard⁸, Sebastien Ottaviani⁹, Paul Ornetti¹⁰, Rene-Marc Flipo¹¹, Bruno Fautrel¹², Jean-Pierre Bertola¹³, Eric Vicaut¹⁴ and Xavier Chevalier¹⁵, ¹Department of Rheumatology, Lariboisière Hospital, AP-HP Université de Paris, INSERM U1132, Paris, ²Department of Rheumatology, Lariboisière Hospital, AP-HP Université de Paris, INSERM U1132, Paris, France, ³AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ⁴CHU Besançon, department of rheumatology, Besancon, France, ⁵Rheumatology Department, Lyon University Hospital, Lyon, France, ⁶CHU Tours, department of rheumatology, Tours, France, ⁷IRMB, University of Montpellier, Inserm U1183, University Hospital of Montpellier, Montpellier, France, ⁸APHP Henri Mondor Hospital, Creteil, France, ⁹Rheumatology Department, Bichat hospital, APHP, Paris, France, ¹⁰CHU Dijon, INSERM CAPS 1093, plateforme d’investigation technologique CIC1432, Dijon, France, ¹¹Lille University Hospital, Lille, France, ¹²Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ¹³CHUGAI PHARMA FRANCE, Paris, France, ¹⁴Clinical Research Unit, Paris, ¹⁵AP-HP, UPEC, Créteil
Background/Purpose: To evaluate the efficacy of tocilizumab, an antibody against interleukin-6 receptor (IL-6R), in patients with hand osteoarthritis.Methods: This was a multicenter, 12-week, randomized, double-blind,…
Abstract Number: 1644 • ACR Convergence 2020
Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis
Ali Guermazi¹, Frank Roemer², Andrew Kompel¹, Luis Diaz³, Michel Crema⁴, Mark Brown⁵, Anne Hickman⁵, Glenn Pixton⁶, Lars Viktrup⁷, Robert Fountaine⁵, Aimee Burr⁵, Sarah Sherlock⁵ and Christine West⁸, ¹Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, and Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ³Boston Veteran Affairs Healthcare System, Boston, MA, ⁴Boston University School of Medicine, Paris, France, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc., Morrisville, NC, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tanezumab is a nerve growth factor monoclonal antibody in development for osteoarthritis (OA). Following a clinical hold due to concerns around adverse joint events,…
Abstract Number: 1660 • ACR Convergence 2020
Sleep Disturbance and Pain Severity and Multi-site Pain: A Prospective 10.7-year Follow-up Study
Feng Pan¹, Jing Tian¹, Flavia Cicuttini² and Graeme Jones¹, ¹University of Tasmania Menzies Institute for Medical Research, Hobart, Tasmania, Australia, ²Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Background/Purpose: Sleep disturbance is often comorbid with chronic pain disorders, with emerging evidence suggesting a stronger effect of sleep disturbance on pain than vice versa;…
Abstract Number: 0537 • ACR Convergence 2020
Hip Abductor Strength and Its Association with New or Worsening Knee Pain: The MOST Study
Cara Lewis¹, Neil Segal², Joshua Stefanik³, Xiaoyang Chen⁴, Glenn Williams⁵, Michael Nevitt⁶, Cora Lewis⁷ and David Felson⁸, ¹Boston University, Brookline, MA, ²University of Kansas Medical Center, Iowa City, IA, ³Northeastern University, Boston, MA, ⁴Boston University, Boston, MA, ⁵Drexel University, Philadelphia, PA, ⁶Department of Epidemiology and Biostatistics, University of California San Francisco, Orinda, CA, ⁷University of Alabama Birmingham, Birmingham, AL, ⁸Boston University School of Medicine, Boston, MA
Background/Purpose: Hip abductors are important for controlling pelvic orientation and rotation of the femur during gait, both of which affect knee mechanics. Thus hip abductor…
Abstract Number: 0703 • ACR Convergence 2020
Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect
Francis Berenbaum¹, Coralie Meurot², Laure Sudre³, Keren Bismuth², Revital Rattenbach², Patrice Denefle², Celine Martin² and Claire Jacques³, ¹AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ²Campus Institut Pasteur Lille, 4P Pharma, Lille, France, ³Inserm, UMR_S938, Hospital Saint-Antoine, Paris, France
Background/Purpose: Osteoarthritis (OA) is an age-related joint disease affecting millions of individuals worldwide and associated with an extremely high burden largely attributable to disability. To…
Abstract Number: 1103 • ACR Convergence 2020
Metacarpo-phalangeal Osteoarthritis Is Not Rare and Is Associated with Mechanical Rather Than Systemic Factors in Hand Osteoarthritis: An Observational Study from a Large Hospital-based Cohort
Inès Kouki¹, Sophie Tuffet², Michel Crema³, Alexandra Rousseau², Pascal Richette⁴, Maxime Dougados⁵, Francis Berenbaum⁶, Jeremie Sellam⁶ and Alice Courties⁶, ¹AP-HP, Sorbonne Université, Service de rhumatologie, Hôpital Saint-Antoine, Paris,, Paris, France, ²AP-HP, Hôpital Saint-Antoine, Unité de Recherche Clinique de l'Est Parisien (URC-Est), Paris, 75012,, Paris, France, ³Boston University School of Medicine, Paris, France, ⁴Department of Rheumatology, Lariboisière Hospital, AP-HP Université de Paris, INSERM U1132, Paris, ⁵Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, ⁶AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France
Background/Purpose: Proximal and distal inter-phalangeal (PIP, DIP) and thumb base joints are the most common sites affected in hand osteoarthritis (HOA), while involvement of metacarpo-phalangeal…
Abstract Number: 1119 • ACR Convergence 2020
Association of Primary Insurance Status on Bilateral Knee Arthroplasty Utilization and Complications: A United States Nationwide Analysis
Bella Mehta¹, Kaylee Ho², Jennifer Bido³, Stavros Memtsoudis³, Michael Parks⁴, Linda Russell⁵, Susan Goodman¹ and Said Ibrahim⁶, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Weill Cornell Medicine, New York, ³Hospital for Special Surgery, New York, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁶Weill Cornell Medicine, Cleveland, OH
Background/Purpose: In patients with end-stage bilateral knee osteoarthritis, treatment options include either a staged total knee arthroplasty (TKA) procedure, often with a few months in…
Abstract Number: 1485 • ACR Convergence 2020
LNA043, a Novel Cartilage Regenerative Treatment for Osteoarthritis: Results from a First-In-Human Trial in Patients with Knee Osteoarthritis
Celeste Scotti¹, Joseph Gimbel², Didier Laurent¹, Aviv Madar³, Thomas Peters¹, Yunyu Zhang³, Florine Polus¹, Michael Beste³, Igor Vostiar¹, Subhajit Choudhury⁴, Nicole Gerwin¹, Jörg Goldhahn⁵, Matthias Schieker¹ and Ronenn Roubenoff¹, ¹Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Arizona Research Center, Phoenix, ³Novartis Institutes for BioMedical Research, Cambridge, ⁴Biostatistics & Pharmacometrics, Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁵Department of Health Sciences and Technology, ETH Zürich, Zurich, Switzerland
Background/Purpose:LNA043 is a modified human angiopoietin-like 3 (ANGPTL3) protein identified in a phenotypic screen for inducers of chondrogenesis and cartilage repair. The primary objective of…
Abstract Number: 1645 • ACR Convergence 2020
Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program
Luana Colloca¹, Robert Dworkin², John Farrar³, Leslie Tive⁴, Ed Whalen⁵, Jerry Yang⁴, Lars Viktrup⁶, Mark Brown⁷, Christine West⁷ and Kenneth Verburg⁸, ¹University of Maryland, Baltimore, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, New York, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Groton
Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].